MSAF imaging - OncoLux Inc.

OncoLux’s’ AURORA™ Multispectral Specimen Imaging Platform is designed for Target Tissue Identification through the detection of Intrinsic Biomolecular Markers using Tissue Autofluorescence Mapping

STEP 1

Multi-Spectral Illumination

STEP 2

Multi-Spectral Detection

STEP 3

Train AI/ML Algorithms

Multispectral Autofluorescence Imaging

OncoLux’s AURORA™ Imaging allows the differentiation of tissue types & structures through differential autofluorescence and direct, diffuse reflectivity imaging

The example illustrates a TURBT specimen in RGB under a false-color three-channel autofluorescence composite image. Different colors and shades represent the different biomolecular constituents present in the tissue.

AURORA’s™ AI-powered imaging distinguishes diseased from normal tissue.

The AURORA™ Specimen Imager is a bench top unit based on our Multi-Spectral Autofluorescence imaging technology, is designed for diseased and normal tissue discrimination and is powered by our tissue classification AI-based algorithms AURORAVision™

Units can be configured for high resolution, small specimen analysis: 10mm dia, and as such is suitable for biopsy specimen analysis. We have launched Aurora targeted for use in non-muscle invasive (NMI) bladder cancer and the analysis of specimens in transurethral resection of bladder tumor (TURBT) procedures.

Real-time imaging during surgery could improve the odds of preserving function and reducing recurrence.

MarginASSUR™ uses AI-powered imaging to detect cancer margins and residual disease.

The OncoLux MarginASSURE™ Specimen Imager is a bench top unit based on Multi-Spectral Autofluorescence imaging technology, is designed for cancer margin and residual cancer discrimination and is powered by our tissue classification AI-based algorithms OncoSight AI™

Real-time imaging during prostatectomy could improve the odds of preservation of function and reduce recurrence for 90,000 men in the U.S. per year.

60% reduction in the breast cancer positive margin rate nationwide could avoid reoperations for 30,000 women annually.

Real-time bladder resection imaging could avoid 70,000 repeat TURBT procedures per year in the U.S.

PROBLEM

Surgeons cannot distinguish cancer from surrounding normal tissue, leading to incomplete tumor removal, unintended patient injury, re-operations and/or higher likelihood of recurrence. This is true in >20% of cancer surgeries creating > $1B per year problem in the U.S.

SOLUTION

The OncoLux Solution: Label free enhanced tissue imaging technology capable of highlighting regions of potential positive margins intraoperatively, providing surgeons actional data to help improve patient outcomes

TODAY

Cancer looks like normal tissue to the surgeon.

TOMORROW

Using Oncolux‘s enhanced imaging, surgeons will see and remove all cancer before closing.

Slide left and right to compare tissue imaging.

We have demonstrated technology in breast bladder & prostate cancers:

Learn More about OncoLux’s Technology and Products

Breast

155 Patients
417 Specimens
LOPO* Cross Validation
88% Accuracy¹

Bladder

98 Patients
173 Specimens
LOPO Cross Validation
90% Accuracy²

Prostate

80 Patients
55 Specimens
LOPO Cross Validation
86% Accuracy³

In general, surgeons attempt to balance clear margins with organ sparing and preservation of post-operative function and are demanding better intraoperative imaging tools to enable more precise surgeries and better outcomes.